Short Interest in Aligos Therapeutics, Inc. (NASDAQ:ALGS) Expands By 46.5%

Aligos Therapeutics, Inc. (NASDAQ:ALGS - Get Free Report) saw a significant increase in short interest in the month of October. As of October 31st, there was short interest totalling 121,300 shares, an increase of 46.5% from the October 15th total of 82,800 shares. Approximately 4.8% of the shares of the company are short sold. Based on an average daily trading volume, of 145,700 shares, the days-to-cover ratio is currently 0.8 days.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a "buy" rating and issued a $75.00 price objective on shares of Aligos Therapeutics in a report on Thursday, November 7th.

Aligos Therapeutics Price Performance

NASDAQ ALGS traded down $0.12 on Thursday, reaching $19.46. 671,502 shares of the company's stock traded hands, compared to its average volume of 68,694. The stock has a 50-day simple moving average of $10.11 and a 200 day simple moving average of $12.51. Aligos Therapeutics has a 12 month low of $6.76 and a 12 month high of $30.00. The stock has a market cap of $62.27 million, a PE ratio of -1.46 and a beta of 2.11.

Aligos Therapeutics (NASDAQ:ALGS - Get Free Report) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($3.07) EPS for the quarter, missing analysts' consensus estimates of ($2.15) by ($0.92). The business had revenue of $1.27 million for the quarter, compared to the consensus estimate of $1.00 million. Aligos Therapeutics had a negative net margin of 1,283.19% and a negative return on equity of 114.34%. During the same period in the previous year, the company earned ($10.25) EPS. As a group, analysts anticipate that Aligos Therapeutics will post -10.36 EPS for the current year.

Institutional Investors Weigh In On Aligos Therapeutics

Several hedge funds have recently bought and sold shares of ALGS. Acadian Asset Management LLC grew its holdings in shares of Aligos Therapeutics by 17.6% during the first quarter. Acadian Asset Management LLC now owns 657,995 shares of the company's stock valued at $644,000 after buying an additional 98,628 shares during the last quarter. Armistice Capital LLC boosted its stake in Aligos Therapeutics by 5.3% during the 2nd quarter. Armistice Capital LLC now owns 7,256,410 shares of the company's stock valued at $2,540,000 after purchasing an additional 363,000 shares during the last quarter. Finally, Opaleye Management Inc. increased its holdings in shares of Aligos Therapeutics by 25.7% in the 1st quarter. Opaleye Management Inc. now owns 1,630,000 shares of the company's stock worth $1,597,000 after purchasing an additional 333,000 shares in the last quarter. Institutional investors own 60.43% of the company's stock.

Aligos Therapeutics Company Profile

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).